ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1550 National Cancer Institute Html en Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma.
red blood cells0.477588
Lymphocyte-depleted Hodgkin lymphoma0.50617
cancer treatment0.499962
malignant tumor cells0.49761
body0.493073
PDQ cancer information0.490723
Non-Hodgkin Lymphoma Treatment0.479804
clinical trial search0.486742
white blood cells0.496539
Low-risk childhood Hodgkin0.469047
Intermediate-risk childhood Hodgkin0.468746
clinical trials0.681512
recurrent hodgkin lymphoma0.512969
cancer information summary0.473675
clinical trial0.539017
-predominant childhood Hodgkin0.466011
blood cells0.515545
weight loss0.482905
refractory Hodgkin lymphoma0.492835
lymph nodes0.518888
sclerosis Hodgkin lymphoma0.505736
radiation therapy0.568298
childhood hodgkin lymphoma0.931364
lymph node groups0.523619
Lymphocyte-rich classical Hodgkin0.468116
treatment0.589509
night sweats0.484683
High-risk childhood Hodgkin0.468559
Hodgkin Lymphoma Treatment0.532549
classical childhood Hodgkin0.485325
low-risk Hodgkin lymphoma0.490968
recurrent childhood Hodgkin0.483388
cancer cells0.532494
cellularity Hodgkin lymphoma0.506213
Untreated childhood Hodgkin0.4689
lymphocyte-predominant Hodgkin lymphoma0.506119
treatment clinical trials0.466252
National Cancer Institute0.485234
lymph vessels0.466622
new treatment0.477189
bone marrow0.510269
PDQ summary0.464519
hodgkin lymphoma0.996696
cancer clinical trials0.496286
classical hodgkin lymphoma0.530289
swollen lymph nodes0.502296
lymphocyte-predominant childhood Hodgkin0.463387
cancer0.737848
information0.498307
CLICK HERE
1613 National Cancer Institute Html en Milk Thistle (PDQ®)–Health Professional Version Expert-reviewed information summary about the use of milk thistle as a treatment for people with cancer.
skin cancer0.626682
silibinin0.690395
Silybum marianum0.601821
cell lines0.721716
silybin0.669258
cell growth0.69811
prostate cancer cell0.66523
silymarin treatment0.604627
cancer cell growth0.625622
body weight0.623855
human prostate carcinoma0.68146
cancer epithelial cells0.601164
glioma cell lines0.609591
isolated compound silymarin0.617496
Cancer Res0.643092
human liver cells0.615903
prostate cancer cells0.651126
prostate carcinoma cells0.621206
liver0.635065
patients0.607034
effects0.642741
mild laxative effect0.607369
Clin Cancer Res0.601341
effect0.675634
flavonoid antioxidant silymarin0.723144
cancer chemopreventive effects0.614128
cancer cells MDA-MB0.601463
et al.0.630532
Biophys Res Commun0.659514
human colorectal cancer0.630373
flavonoid hepatoprotector silymarin0.616137
cancer cells0.687834
cancer cell lines0.67658
Biochem Biophys Res0.658799
PUBMED Abstract0.644662
ovarian cancer cells0.604482
Silymarin effects0.60576
studies0.607771
liver function tests0.604338
breast cancer cell0.607955
cancer cell lines.0.620697
silymarin0.927821
silymarin stimulates synthesis0.619814
cell cycle0.608497
Abstract0.706375
prostate cancer0.673752
cancer0.736552
dietary silymarin0.618331
milk thistle0.829966
CLICK HERE
1890 National Cancer Institute Html es Tratamiento del cáncer de seno (mama) (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama).
estadio lllC0.524041
siguientes procedimientos0.510716
siguientes aspectos0.534365
causa efectos0.516747
estadio lllB0.524512
estadio lllA0.524967
rayos x0.508877
causó hinchazón0.508591
cuáles lesiones0.508991
Breast Cancer Risk0.519727
epidérmico humano tipo0.51911
carcinoma lobulillar0.618686
crecimiento llamada her20.513006
cuerpo llamada ecograma0.530459
pared torácica.ampliar mastectomía0.517551
siguientes estadios0.514163
proteína tipo factor0.510936
células madre0.671831
estadio iv0.594708
ganglio linfático centinela0.990128
Oncotype DX0.510563
estadio ib0.547143
prueba ayuda0.524997
enlace drugs approved0.56421
estadio ia0.546556
mama.ampliar cirugía0.509968
CLIS.Ampliar Carcinoma lobulillar0.520349
efectos tardíos0.515275
proteína her20.510017
Características genéticas0.510197
bulbos minúsculos0.511767
Breast Cancer Treatment0.519669
cuántos genes0.511329
incisión separada.ampliar mastectomía0.517497
estadio iiia0.543785
antecedentes familiares0.532316
cabo pruebas0.51404
estadio iiic0.596075
estadio llB0.525023
estadio llA0.525437
Gynecologic Cancers0.511174
mama.ampliar mamografía0.511179
proteína llamada mTOR0.510238
Breast Cancer0.623769
sección cáncer0.744984
pequeñas llamadas lobulillos0.518854
genes brca10.512161
siguientes pruebas0.535819
siguientes sumarios0.517679
CLICK HERE
3447 National Cancer Institute Html es Consumo de cigarrillo: riesgos para la salud y cómo dejar de fumar (PDQ®)–Versión para pacientes Sumario de información revisada por expertos sobre la investigación y pautas que se enfocan en la prevención y el cese de fumar.
inglés quitguide0.387847
voluntarios sanos0.399525
mejores formas0.386123
siguientes afecciones0.472657
tabaco causa0.867887
siguientes productos0.425294
menor cantidad0.421673
largo plazo0.418123
cuánto tiempo0.427364
Salud Pública0.42102
PDQ Consumo0.504465
Lung Health Study0.500728
inglés llamadas tratamiento0.496113
National Cancer Institute0.439195
Más personas0.44409
siguientes riesgos0.405102
Instituto Nacional0.538387
Leucemia mieloide aguda0.525345
importantes beneficios0.399221
Physician Data Query0.786005
Estados Unidos0.979435
prevención revisa0.406999
Internet www.espanol.smokefree.gov0.394612
siguientes medidas0.45081
siguientes recursos0.434379
principal causa0.695094
Public Health Service0.49625
tabaco encendido0.560371
Quit Smoking Today0.481661
enfermedades respiratorias0.409989
CLICK HERE
3516 National Cancer Institute Html en Phases of Clinical Trials Information about the phases of cancer clinical trials. If a new treatment is successful in one phase, it will proceed to further testing in the next phase.
phase0.792058
new treatment0.947877
trial phases0.360482
current standard therapy0.316008
new cancer treatments0.34108
phase clinical trials0.478655
early phases0.271363
phases0.375183
drug treatment trials0.287914
CLICK HERE
15607 National Cancer Institute Html en RAS Spokes/Funding null
Target KRAS-driven Cancer0.470287
Memorial Sloan Kettering0.519803
postdoctoral fellowship awardees0.536142
mutant KRAS genes0.739519
Kettering Cancer Center0.57102
cell lung cancers0.454
KRAS-Dependent Synthetic Lethality0.494023
synthetic lethalities0.645951
Oncogenic KRAS Synthetic0.736037
pancreatic cancer research0.594341
colorectal cancer0.483021
Stanford University School0.433776
cancer patient-derived organoids0.505737
Sloan Kettering Cancer0.56303
patient-derived xenografts0.489445
mutant KRAS0.946717
pancreatic cancer community0.516641
human lung cancers0.451785
small molecule screens0.437567
Pancreatic Cancer Action0.760787
mouse models0.516476
Cancer Research Center0.504949
RAS team0.447514
KRAS co-dependencies0.626256
KRAS research0.731632
cancer research0.612188
pancreatic cancer0.855519
RAS Initiative workshop0.507302
KRAS Synthetic Lethal0.86327
KRAS Mutant Lung0.726016
common mutant KRAS0.721287
activity-based proteomic screens0.446336
Finding KRAS Vulnerabilities0.720626
PanCan KRAS Postdoctoral0.721221
Frederick National Laboratory0.644503
Synthetic Lethal Interactors0.486265
Synthetic Lethality Screens0.508669
Mutant KRas-Dependent Cancers0.505292
KRAS effector pathways0.684876
Cancer Action Network0.707609
Deaconess Medical Center0.441844
KRAS effectors0.653247
Synthetic Lethal Relationships0.482397
RAS Initiative0.631295
colorectal cancer cells0.482928
function high-throughput screens0.439806
different KRAS mutations0.711715
Synthetic Lethality0.582272
CLICK HERE
15662 National Cancer Institute Html en Cancer Disparities Basic information about cancer disparities in the U.S., factors that contribute to the disproportionate burden of cancer in some groups, and examples of disparities in incidence and mortality among certain populations.
bile duct cancer0.529873
colorectal cancer deaths0.551836
colorectal cancer screening0.555974
racial/ethnic minority groups0.531719
cancer disparities—in particular0.523151
racial/ethnic groups0.863683
behavioral risk factors0.505154
triple-negative breast cancer0.524689
colorectal cancer0.712116
key cancer incidence0.561455
Asian Pacific Islanders0.491901
cancer types0.491276
racial/ethnic differences0.492357
aggressive prostate cancers0.499019
population groups0.55611
white women0.564935
higher death rates0.607232
cancer health disparities0.660515
higher rates0.558073
prostate cancers0.505687
clinical trial participation0.493429
mortality disparities0.547391
quality health care0.505421
U.S. racial/ethnic groups0.529263
United States0.628581
minority racial/ethnic groups0.535197
African Americans0.773054
certain groups0.517997
dense urban neighborhoods0.497746
African American men0.689721
higher socioeconomic status0.531761
cancer measures0.502411
excessive alcohol intake0.493381
higher cancer burden0.573329
environmental risk factors0.507025
health care0.541481
African American women0.787066
colorectal cancer incidence0.649355
American Indians/Alaska Natives0.584845
specific disparities0.531133
medically underserved individuals0.505673
effective health care0.506095
breast cancer0.54205
statewide colorectal cancer0.547339
biological differences0.594269
cancer disparities0.882383
late-stage cancer0.50232
prostate cancer0.522723
cancer0.915156
CLICK HERE
16636 National Cancer Institute Html en Medicinal Mushrooms (PDQ®)–Patient Version Expert-reviewed information summary about the use of medicinal mushrooms as a treatment for people with cancer.
cancer treatment0.568036
chemotherapy0.524006
PDQ cancer information0.669265
lung cancer0.653736
turkey tail0.777237
reishi0.530583
clinical trials0.606551
U.S. Food0.502811
cancer information summary0.619393
alternative cancer therapies0.507487
clinical trial0.529456
colorectal cancer0.606284
patients0.718186
cancer patients0.586364
gastric cancer patients0.525923
PSK0.651884
adjuvant therapy0.587394
randomized clinical trial0.511048
standard cancer treatments0.505852
NCI PDQ cancer0.523643
reishi mushrooms0.522541
complementary therapies0.52479
radiation therapy0.555862
Therapies Editorial Board0.505693
medicinal mushrooms0.712501
Complementary Therapies Editorial0.519822
Drug Administration0.559401
Cancer Information Specialist0.499441
Cancer Information Service0.564175
advanced lung cancer0.497196
standard cancer treatment0.517619
dietary supplements0.500703
National Cancer Institute0.663466
long time0.498745
alternative medicine0.537174
lung cancer patients0.520738
gastric cancer0.558768
turkey tail mushrooms0.548558
traditional Chinese medicine0.562629
breast cancer0.533457
health0.507834
animal studies0.621773
natural killer cells0.503348
active compound PSK0.527105
alternative therapies0.524113
cancer information summaries0.503919
comprehensive cancer information0.503793
cancer0.900533
CLICK HERE
16858 National Cancer Institute Html en Monitoring Research Grant Awards NCI grants management staff regularly monitor individual grants within each budget period and within the overall project period.
program director0.901745
overall project period0.737705
Comptroller General0.577687
documents0.447442
Grants management officer0.721935
grants management specialist0.810551
federal regulation0.560169
HHS awarding agency0.720873
NCI staff work0.714177
assessment0.459846
progress reports0.591992
budget period0.591377
review0.454674
weaknesses0.464168
grants management0.917818
telephone numbers0.566417
financial reports0.599567
required retention period0.705874
reasonable access0.563534
grant awards0.568767
responsible GMS0.614785
award process0.554431
approved project0.590335
recipients0.469243
recipient cash expenditure0.886855
NCI grants management0.812999
problems0.44631
recipient institution0.874163
United States0.564008
records0.447146
audit reports0.592365
site visits0.586368
scientific progress0.547344
Inspector General0.563508
mutually agreeable course0.708418
recipient’s inability0.723309
internal controls0.570063
Expenditure patterns0.599349
financial systems0.589323
pass-through entity0.56408
monitors individual grants0.762977
applicant organization0.594032
unrestricted access0.5713
principal investigator0.553317
financial management0.584417
specific guidelines0.567884
management systems0.560429
economic policy0.555241
grant expenditures0.689873
CLICK HERE
17291 National Cancer Institute Html es Uso de recursos fidedignos Información para ayudarle al público a evaluar las fuentes y la credibilidad de la información de salud impresa o disponible en Internet.
información personal0.935578
siguientes preguntas0.82336
conocimientos del cáncer que0.776836
Comisión Federal0.674467
Clinical Oncology0.664087
American Society0.659703
numerosos sitios0.822963
acepte recomendaciones0.778707
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.